Global Covid-19 Vaccine Market Growth (Status and Outlook) 2022-2028

Global Covid-19 Vaccine Market Growth (Status and Outlook) 2022-2028

Product Code:183569

Published Date: Jan 12,2022

Pages: 124

Region: Global

Category: Medical Care

PDF DOWNLOAD

GET FREE SAMPLE

CUSTOMIZE REQUEST

PDF DOWNLOAD

GET FREE SAMPLE

CUSTOMIZE REQUEST

SELECT A FORMAT

ADD TO BASKET

BUY NOW

Provide comprehensive and accurate analysis and reports according to your exact requirements

Provide comprehensive and accurate analysis and reports according to your exact requirements

CONTACT US

As the global economy mends, the 2021 growth of Covid-19 Vaccine will have significant change from previous year. According to our (LP Information) latest study, the global Covid-19 Vaccine market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Covid-19 Vaccine market size will reach USD  million in 2028, growing at a CAGR of  % over the analysis period.

The United States Covid-19 Vaccine market is expected at value of US$  million in 2021 and grow at approximately  % CAGR during review period. China constitutes a  % market for the global Covid-19 Vaccine market, reaching US$  million by the year 2028. As for the Europe Covid-19 Vaccine landscape, Germany is projected to reach US$  million by 2028 trailing a CAGR of  % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at  % and  % respectively for the next 5-year period.

Global main Covid-19 Vaccine players cover Inovio Pharmaceuticals, Takis Biotech (Evvivax), Zydus Cadila, and Codagenix, Inc., etc. In terms of revenue, the global largest two companies occupy a share nearly  % in 2021.

This report presents a comprehensive overview, market shares, and growth opportunities of Covid-19 Vaccine market by product type, application, key players and key regions and countries.

Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.
    DNA
    Live Attenuated Virus
    NonReplicating Viral Vecto
    Protein Subunit
    RNA

Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.
    Treatment
    Prevention

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
    Inovio Pharmaceuticals
    Takis Biotech (Evvivax)
    Zydus Cadila
    Codagenix, Inc.
    GeoVax, Inc.
    Bravovax
    Janssen Pharmaceutical Companies
    Altimmune
    Vaxart
    CanSino Biologics
    ExpreS2ion Biotechnologies ApS
    Clover Biopharmaceuticals
    GSK
    Vaxil Bio Ltd.
    Generex
    Novavax, Inc.
    Sanofi Pasteur
    Baylor
    iBio, Inc.
    Zydus Cadila
    Moderna, Inc.
    Curevac
    ImmunoPrecise